THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.

CREDENT CONNECT N CARE LIMITED

THE EQUITY SHARES OF THE COMPANY WILL GET LISTED ON THE SME PLATFORM OF THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE EMERGE")

Our Company was originally incorporated as a Private Limited Company under the name of "Credent Cold Chain Logistics Private Limited" on June 25, 2015 under the provisions of the Companies Act, 2013 with the Registrar of Companies, Delhi bearing CIN: U63000DL2015PTC281994. Further in order to align the name of our Company with the objects of the Company and, pursuant to Special Resolution passed by the shareholders at the Extra Ordinary General Meeting held on January 12, 2024, the name of our Company was changed from "Credent Cold Chain Logistics Private Limited" to "Credent Connect N Care Private Limited" and a fresh certificate of incorporation consequent upon Change of Name was issued by the Registrar of Companies, CPC vide certificate dated May 10, 2024 bearing CIN: U63000DL2015PTC281994. Further, pursuant to a special resolution passed by the shareholder at extra Ordinary General Meeting held on September 15, 2025, company has converted from Private Limited to public limited and name of the company was changed from "Credent Connect N Care Private Limited" to "Credent Connect N Care Limited" and a fresh certificate of incorporation consequent upon conversion into public limited was issued by the Registrar of Companies, CPC vide certificate dated October 28, 2025 bearing CIN: U63000DL2015PLC281994.

Our company is a healthcare services provider engaged in delivering integrated logistics, workforce solutions, and technology-enabled support to healthcare institutions across India. We provide comprehensive operational and logistics services to diagnostic laboratories, In Vitro Diagnostics (IVD) companies, pharmaceutical companies, clinics, and other healthcare enterprises through end-to-end solutions. Our offerings majorly include home sample collection through trained phlebotomists; Operations & Supply Chain Services through stationed phlebotomy teams at laboratories and hospitals; deployment of skilled laboratory technicians and paramedical staff for internal operations; and specialized inter-state and intra-state logistics services. Our logistics solutions ensure temperature-controlled and Turnaround time (TAT) sensitive movement of blood samples and other healthcare products.

a) We derive a significant portion of our revenue from operations from our top 10 customers with which we do not have any firm commitments. The loss of any one or more of our major customers would have a material adverse effect on our business, cash flows, results of operations and financial condition.

b) Our business is dependent on diagnostic and healthcare companies, and any reduction in their testing volumes, outsourcing requirements, or adverse sector developments could materially and adversely affect our business, financial condition, and results of operations.

c) We are exposed to risks relating to loss, damage, contamination or delay in transportation of diagnostic samples, which could result in client claims, financial liabilities and reputational harm.

d) Our business depends on service-level contracts with clients that are subject to renewal, renegotiation and termination, and our inability to maintain or renew such contracts on favourable terms could materially and adversely affect our business.

e) Our business is working capital intensive and trade receivables constitute a significant portion of our current assets. Any delay or failure in realisation of trade receivables could adversely affect our cash flows, liquidity and financial condition.

f) Our business is highly dependent on the availability and performance of a large, skilled and geographically dispersed workforce, and our inability to effectively manage, train and retain such personnel could adversely affect our operations.

g) Our operations depend on the continuous availability of specialised packaging materials and consumables, and any disruption in their supply or increase in their cost could adversely affect our service delivery and profitability.

h) Misconduct, fraud, negligence or theft by our field personnel could adversely affect our business, reputation and financial condition.

i) Our subsidiary companies has incurred losses and had a negative net worth in the past, and any future losses may adversely affect its financial condition and our consolidated results.

j) We rely on financing from banks or financial institutions to carry on our business operations, and inability to obtain additional financing on terms favorable to us or at all could have an adverse impact on our financial condition. If we are unable to raise additional capital, our business and future financial performance could be adversely affected.

k) The BRLM associated with the Issue has handled 64 Public Issues in the past three years, out of which 4 issues were closed below the Issue/Offer Price on listing date:

l) Average cost of acquisition of Equity Shares held by the Promoters is

m) The Price/ Earnings ratio based on Diluted EPS for Fiscal 2026 for the company at the upper end (Rs. 189) of the Price Band is 13.55

n) Weighted Average Return on Net worth for Fiscals 2026, 2025 and 2024 is 29.03%.

o) The Weighted average cost of acquisition of all Equity Shares transacted in the last one year, 18 months and three years from the date of Prospectus is as given below:

p) The Weighted average cost of acquisition compared to Floor Price and Cap Price.

*Price adjusted after bonus issue is Rs. 30.90 per share.

The Issue was made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 253 of the SEBI ICDR Regulations, as amended, wherein not more than 50% of the Net Issue was made available on a proportionate basis to Qualified Institutional Buyers ("QIBs", the "QIB Portion"), provided that our Company may, in consultation with the Book Running Lead Managers, allocated 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which 40% of such Anchor Investor Portion was reserved for, (i) 33.33% was made available for allocation to domestic Mutual Funds, and (ii) 6.67% for life insurance companies and pension funds, subject to valid Bids have being received from domestic Mutual Funds, life insurance companies and pension funds at or above the Anchor Investor Allocation Price. In the event of under-subscription in (ii) above, the allocation was made to domestic Mutual Funds in accordance with the SEBI ICDR Regulations. Further, 5% of the Net QIB Portion was made available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion was made available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion was added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Issue was made available for allocation on a proportionate basis to Non-Institutional Bidders (of which one third of the Non-Institutional Portion was reserved for Bidders with an application size of more than two lots and up to such lots equivalent to not more than Rs. 10 lakhs and two-thirds of the Non Institutional Portion was reserved for Bidders with an application size exceeding Rs. 10 lakhs) and undersubscription in either of these two sub-categories of Non-Institutional Portion was allocated to Bidders in the other subcategory of Non-Institutional Portion, subject to valid Bids have being received at or above the Issue Price and not less than 35% of the Net Issue was made available for allocation to Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids have being received at or above the Issue Price. All potential Bidders (except Anchor Investors) were required to mandatorily utilize the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of Individual Bidders using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts was blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors were not permitted to participate in the Anchor Investor Portion of the Issue through the ASBA process. For details, see "Issue Procedure" beginning on page 271 of the Prospectus.

The investors are advised to refer to the Prospectus for the full text of the Disclaimer clause pertaining to NSE. For the purpose of this Issue, the designated Stock Exchange will be the NSE Limited. The trading will commence on Thursday, August 20, 2026.

The bidding for Anchor Investors opened and closed on Wednesday, August 12, 2026. The Company received 10 Anchor Investors applications for 16,68,000 Equity Shares. The Anchor Investor Allocation price was finalized at Rs. 189 per Equity Share. A total of 14,04,000 Equity Shares were allotted under the Anchor Investors portion aggregating to Rs. 26,53,56,000.

The Issue (excluding Anchor Investors Portion) received 231,176 Applications for 509,128,200 Equity Shares (after considering invalid bids, Other than RC10 Transaction declined by Investors, RC10 Mandate not accepted by Investors and Withdrawal/ Cancelled Bids reported by SCSB and all rejections) resulting 142.85 times subscription (including reserved portion of market maker, and excluding anchor investor portion). The details of the Applications received in the Issue from various categories are as under (before rejections):

A summary of the final demand as per NSE as on the Bid/ Issue Closing Date at different Bid prices is as under:

The Basis of Allotment was finalized in consultation with the designated Stock Exchange, being National Stock Exchange of India Limited ("NSE Emerge") on August 18, 2026.

1. Allotment to Individual Investors (after rejections):

The Basis of Allotment to the Individual Investors, who have Bid at or above the Issue Price of Rs. 189 per equity share, was finalized in consultation with NSE. The category has been subscribed to the extent of 136.72391 times i.e., for 226,414,800 equity shares, the total number of equity shares allotted in this category is 1,656,000 equity share to 1,380 successful applicants. The details of the Basis of Allotment of the said category are as under:

2. Allotment to Non-Institutional Investors (More than 2 lots and up to Rs. 10,00,000) (after rejections):

The Basis of Allotment to the Non-Institutional Investors, who have bid at the Issue Price of Rs. 189 or above per equity share was finalized in consultation with NSE. The category has been subscribed to the extent of 137.52020 times i.e., for 32,674,800 equity shares, the total number of equity shares allotted in this category is 237,600 equity shares to 132 successful applicants. The details of the Basis of Allotment of the said category are as under:

3. Allotment to Non-Institutional Investors (More than Rs. 10,00,000) (after rejections):

The Basis of Allotment to the Non-Institutional Investors, who have bid at the Issue Price of Rs. 189 or above per equity share was finalized in consultation with NSE. The category has been subscribed to the extent of 257.39796 times i.e., for 121,080,000 equity shares, the total number of equity shares allotted in this category is 470,400 equity shares to 261 successful applicants. The details of the Basis of Allotment on sample basis of the said category are as under (sample basis):

Please Note : 1 (One) lot of 1800 shares have been allocated to all the 278 Non Allottees Applicants in Categories with ZERO/NO Allotment in the ratio of 4:278

Please Note : 1 (One) lot of 600 shares have been allocated to all the 261 Successful Applicants from all the Categories in the ratio of 1 : 261

4. Allotment to Market Maker: The Basis of Allotment to Market Maker who have bid at Issue Price of Rs. 189 per equity shares or above, was finalized in consultation with NSE. The category was subscribed by 1.00 times i.e., for 252,000 equity shares, the total number of shares allotted in this category is 252,000 equity shares to 1 successful applicant. The category wise details of the Basis of Allotment are as under:

5. Allotment to QIBs excluding Anchor Investors (after rejections):

The Basis of Allotment to QIBs, who have bid at Issue Price of Rs. 189 per Equity Shares or above, was finalized in consultation with NSE. The category was subscribed by 129.85253 times i.e., 123,052,800 equity shares. As per the SEBI Regulations, 5% of Net QIB portion was reserved for mutual funds i.e., 47,400 equity shares and other QIBs and unsatisfied demand of Mutual Funds were allotted the remaining available equity shares i.e., 900,600 equity shares on a proportionate basis. The total number of shares allotted in this category is 948,000 equity shares to 91 successful applicants. The category wise details of the Basis of Allotment are as under:

6. Allotment to Anchor Investors (after rejections):

The Company in consultation with the BRLM has allocated 1,404,000 Equity Shares to 10 Anchor Investors at the Anchor Investor Issue Price of Rs. 189 per equity shares in accordance with the SEBI (ICDR) Regulations. This represents upto 60% of the QIB Category.

The Board of Directors of our Company at its meeting held on August 18, 2026 has taken on record the basis of allotment of equity shares approved by the designated Stock Exchange, being NSE and has allotted the equity shares to various successful applicants. The Allotment Advice Cum Refund Intimation have been dispatched to the address of the investors as registered with the depositories. Further, instructions to the SCSBs have been dispatched/ mailed for unblocking of funds and transfer to the Public Issue Account on August 18, 2026. In case the same is not received within ten days, investors may contact the Registrar to the Issue at the address given below. The Equity Shares allotted to the successful allottees shall be uploaded on August 19, 2026 for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company has filed Listing Application to NSE on August 19, 2026. The Company has received the listing and trading approval from NSE, and trading will commence on August 20, 2026.

Note: All capitalized terms used and not defined herein shall have the respective meanings assigned to them in the Prospectus.

The details of the allotment made was hosted on the website of the Registrar to the Issue, Kfin Technologies Limited.

All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the First/ Sole Bidder Serial number of the ASBA form, number of Equity Shares bid for, Bidder DP ID, Client ID, PAN, date of submission of the Bid cum Application Form, address of the Bidder, the name and address of the Designated Intermediary where the Bid cum Application Form was submitted by the Bidder and copy of the Acknowledgment Slip received from the Designated Intermediary and payment details at the address given below:

	KFIN TECHNOLOGIES LIMITED
	Reg. Office: 301, The Centrium, 3rd Floor, 57, Lal Bahadur Shastri Road, Nav Pada, Kurla (West), Mumbai - 400070, Maharashtra
	Corp. Office: Selenium Tower-B, Plot 31 & 32, Gachibowli, Financial District, Nanakramguda, Serilingampally, Hyderabad - 500 032, Telangana
	Telephone: +91 40-6716 2222 ; Email: credentconnect.ipo@kfintech.com;
	Investor Grievance Email: einward.ris@kfintech.com ; Website: www.kfintech.com
	Contact Person: M. Murali Krishna; SEBI Regn. No.: INR000000221

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF CREDENT CONNECT N CARE LIMITED

Disclaimer: Credent Connect N Care Limited has filed the Prospectus with the RoC on August 19, 2026 and thereafter with SEBI and the Stock Exchange. The Prospectus is available on the website of the BRLM, Hem Securities Limited at www.hemsecurities.com and the Company at https://c3logistics.co.in/ and shall also be available on the website of the NSE and SEBI. Investors should note that investment in Equity Shares involves a high degree of risk and for details relating to the same, please see "Risk Factors" beginning on page 20 of the Prospectus.